Webinar Recap: The Impact of 340B Reimbursement Cuts on AACI Cancer Centers

Since the Centers for Medicare and Medicaid Services (CMS) reimbursement cuts to the 340B drug pricing program went into effect January 1, AACI has been advocating to protect the program. CMS slashed what Medicare pays 340B hospitals for many oncology infusions and other physician-administered drugs, reducing reimbursement rates by nearly 30 percent. As a result, several AACI cancer centers have eliminated jobs, suspended faculty recruitment, and cut back on important educational programming. Among those hit hardest by the cuts are cancer centers and safety-net hospitals that care for low-income and rural patients, compounding cancer health disparities in the U.S.

As a continuation of its ongoing advocacy efforts, AACI hosted a webinar on Friday, September 14, titled “The Impact of 340B Reimbursement Cuts on AACI Cancer Centers.” Featured presenters were Jeff Davis, senior advisor and of counsel at Baker Donelson; Cheryl L. Willman, MD, CEO and director of University of New Mexico Comprehensive Cancer Center (UNMCCC); and Sandra F. Durley, PharmD, senior associate director of ambulatory care pharmacy services at UI Health. AACI Deputy Director Jennifer Pegher moderated the webinar.

Following a detailed overview of the 340B program and its original intent from Mr. Davis, Dr. Willman described the negative repercussions of 340B program cuts she has already encountered at the UNMCCC.

“The excellent outcomes that we desire for our patients require access to clinical trials and many new cancer treatment modalities,” said Dr. Willman. “These include precision medicine, genome sequencing, targeted therapies, immunotherapies, and new experimental therapies – often of an exceedingly high cost.”

Through robust data, Dr. Durley described the financial impact on UI Health, where, she pointed out, oncology-related purchases accounted for 52 percent of 340B spending in Fiscal Year 2018.

She also shared moving patient stories, including that of I.H., an uninsured 30-year-old-man who was able to receive $5,700 worth of medication to treat acute myeloid leukemia for only $20, thanks to 340B discounts and the Medication Assistance Program.

“I wanted nothing more than to get well,” I.H. said. And he did: I.H. is still in remission today.

More than 80 participants—including cancer center directors, administrators, finance officers, and clinical trials office managers—tuned in to the webinar, which is just one facet of AACI’s advocacy efforts to preserve the 340B program.

AACI is still collecting responses to its 340B Impact Survey. And we encourage member centers to participate in our advocacy efforts by writing op-eds, contacting their state’s Senators and Congressional representatives, sharing social media posts using the hashtag #Protect340B, and submitting their comments to CMS by Monday, September 24. Please contact AACI for sample op-eds and supplemental educational resources on the program.

Download the webinar slides.
Download the audio recording.

Pictured (left to right): Jeff Davis, Dr. Cheryl L. Willman, Dr. Sandra F. Durley  

 

 

Advertisements

A Legislation Library to Benefit AACI Cancer Centers

Roy Jensen, MD

Roy A. Jensen, MD

Cancer centers are an enormous force for good and collectively have worked to lower cancer incidence and mortality rates for over four decades. In many cases, this improvement has resulted from basic science advances being translated into the clinic for the benefit of cancer patients. But in other cases, cancer centers worked diligently to prevent cancer from developing in patients in the first place. This has primarily resulted from the enactment of good public policy that limits carcinogen exposures or promotes the adoption of healthy behaviors in large populations. Such efforts can often save hundreds—if not thousands—of lives over the course of many years and represent a critical tool in our efforts to lower cancer mortality.

As a membership organization serving 98 cancer centers in the United States and Canada, the Association of American Cancer Institutes (AACI) has an unprecedented opportunity to exert enormous influence on public policy. I suspect nearly every AACI cancer center in our organization is working to advance at least one public policy initiative, however we haven’t been able to leverage our collective efforts for maximum impact.

At the upcoming AACI/CCAF Annual Meeting, September 30 to October 2 in Chicago, I will begin my two-year term as president of AACI. For my presidential initiative, I intend to spearhead the development of a comprehensive, cancer-specific clearinghouse of model legislation for AACI cancer centers to share with their state/province legislators.

My hope is to offer a dynamic, online library of model policies – each of which is the product of many hours of research and data collection. Using this framework, I believe AACI would be positioned to become a “one-stop shop” for cancer-related public policy. AACI will not engage in formal lobbying; however, the database will serve as a go-to source for information that AACI’s members can use to educate legislators on the issues vital to decreasing cancer incidence and mortality in their catchment area.

Read more from Dr. Jensen, CEO and director of The University of Kansas Cancer Center and AACI vice president/president-elect, in AACI’s September 2018 Commentary

Member Spotlight: September 2018

Albert Einstein Cancer Center

Albert Einstein Cancer Center

The Albert Einstein Cancer Center, in the Bronx, NY, was established in 1971 and was among the first academic cancer research centers to be funded by the National Cancer Institute (NCI), a designation continuously held since 1972. Today the center comprises more than 150 members from 18 academic departments at the Albert Einstein College of Medicine, fostering basic, clinical, population, and translational research to better understand the origins of cancer and its effective detection, prevention, and treatment.

The University of Chicago Medicine Comprehensive Cancer Center

University of Chicago MedicineFounded in 1973, The University of Chicago Medicine Comprehensive Cancer Center received its NCI designation that year and its comprehensive cancer center designation in 2008. Patient care takes place at University of Chicago Medicine, where more than 4,000 cancer patients are diagnosed and/or treated annually. The 10-story Center for Care and Discovery, a hospital opened in 2013, includes an entire floor for cancer treatment, including a 28-bed stem cell and bone marrow transplant unit.

UNC Lineberger Comprehensive Cancer Center

Lineberger Comprehensive Cancer CenterUNC Lineberger Comprehensive Cancer Center, in Chapel Hill, NC, is one of only 49 NCI-Designated Comprehensive Cancer Centers and was rated as “exceptional”—the highest category—by the NCI. The center was named for the Lineberger family, pioneers in the textile industry. In 1977, the Lineberger Foundation pledged $1 million to a building fund that provided the core financing for the original three-story research building that opened in 1984.

Monthly Links Roundup: August 2018

This month, we announced that Karen E. Knudsen, PhD, enterprise director of Sidney Kimmel Cancer Center (SKCC) – Jefferson Health in Philadelphia, has been elected vice president/president-elect of the AACI Board of Directors.

Dr. Knudsen will be joined by four other new board members:

Randall F. Holcombe, MD, MBA
, University of Hawai‘i Cancer Center
Thomas P. Loughran, Jr., MD, UVA Cancer Center
Leonidas (Leon) Platanias, MD, PhD, Robert H. Lurie Comprehensive Cancer Center
Benjamin G. Neel, MD, PhD, Laura and Isaac Perlmutter Cancer Center at NYU Langone

The new members will officially join the board at our AACI/CCAF Annual Meeting, September 30 – October 2 in Chicago.

We highlighted Richard and Susan Rogel, recipients of the inaugural Champion for Cures Award, and Charles M. Perou, PhD, who will receive the AACI Distinguished Scientist Award at the annual meeting on October 1.

During the dog days of summer, we shared sun safety tips for Summer Sun Safety Month.

We highlighted the importance of HPV vaccination during National Immunization Awareness Month and encouraged AACI members to nominate exceptional physicians for the HPV Vaccination Champion Award.

Coming up in September:

Events:

Thursday, September 13 |Rally for Medical Research Capitol Hill Day – Washington, DC
Friday, September 21 | Biden Cancer Summit – Washington, DC
Sunday, September 30 – Tuesday, October 2 | AACI/CCAF Annual Meeting – Chicago, IL

Awareness Campaigns:

  • Blood Cancer/Leukemia and Lymphoma Awareness Month
  • Childhood Cancer Awareness Month
  • Gynecologic Cancer Awareness Month
  • National Ovarian Cancer Awareness Month
  • National Prostate Cancer Awareness Month
  • Thyroid Cancer Awareness Month